Triazikvon
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
2,3,5-tris(aziridin-1-il)benzo-1,4-hinon | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 68-76-8 | ||
ATC kod | L01AC02 | ||
PubChem[1][2] | 6235 | ||
UNII | F3D5D9P25I ![]() | ||
KEGG[3] | C19542 ![]() | ||
Hemijski podaci | |||
Formula | C12H13N3O2 | ||
Mol. masa | 231,25 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Sinonimi | 2,3,5-Tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
Triazikvon je lek koji se koristi u hemoterapiji.
On je alkilirajući agens. On može da reaguje sa DNK da formira međulančane veze.[4]
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Begleiter A (November 2000). „Clinical applications of quinone-containing alkylating agents”. Front. Biosci. 5: E153–71. DOI:10.2741/begleit. PMID 11056078.
Spoljašnje veze
![]() | Portal Medicina |
![]() | Portal Hemija |
- p
- r
- u
(M faza)
Blokiranje formiranja microtubule | |
---|---|
Blokiranje rasformiranja microtubule |
DNK replikacije
| |||||||||
|
FI (Tipifarnib) • CDK inhibitori (Alvocidib, Seliciklib) • PrI (Bortezomib) • PhI (Anagrelid) • IMPDI (Tiazofurin) • LI (Masoprokol) • PARP inhibitor (Olaparib) • HDAC (Vorinostat, Romidepsin) | |
Receptorski antagonisti | |
Drugi/negrupisani | Amsakrin • Trabektedin • retinoidi (Alitretinoin, Tretinoin) • Arsen trioksid • asparaginski iscrpljivači (Asparaginaza/Pegaspargaza) • Celekoksib • Demekolcin • Elesklomol • Elsamitrucin • Etoglucid • Lonidamin • Lukanton • Mitoguazon • Mitotan • Oblimersen • mTOR inhibitori (Everolimus, Temsirolimus) |